Natera (NASDAQ:NTRA) PT Raised to $100.00

Natera (NASDAQ:NTRA) had its price target hoisted by stock analysts at The Goldman Sachs Group from $90.00 to $100.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 8.06% from the stock’s current price.

Other analysts have also issued research reports about the stock. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. Stephens reissued an “overweight” rating and issued a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. Craig Hallum began coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Finally, Canaccord Genuity Group increased their price target on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Natera Stock Down 2.0 %

Natera stock traded down $1.93 during midday trading on Monday, hitting $92.54. 186,955 shares of the stock were exchanged, compared to its average volume of 1,467,696. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $11.18 billion, a price-to-earnings ratio of -24.45 and a beta of 1.37. Natera has a 52-week low of $36.90 and a 52-week high of $98.82. The business’s 50-day moving average price is $84.14 and its 200-day moving average price is $64.60.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. On average, research analysts expect that Natera will post -2.35 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,958 shares of Natera stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28. Following the transaction, the chief executive officer now owns 175,550 shares of the company’s stock, valued at $11,965,488. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Michael Burkes Brophy sold 2,202 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $65.86, for a total value of $145,023.72. Following the transaction, the chief financial officer now owns 65,754 shares of the company’s stock, valued at $4,330,558.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven Leonard Chapman sold 1,958 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $68.16, for a total transaction of $133,457.28. Following the completion of the transaction, the chief executive officer now directly owns 175,550 shares in the company, valued at approximately $11,965,488. The disclosure for this sale can be found here. Insiders have sold 366,477 shares of company stock valued at $28,552,682 over the last 90 days. 9.42% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently bought and sold shares of NTRA. RiverPark Advisors LLC purchased a new stake in Natera during the fourth quarter valued at $27,000. Principal Securities Inc. purchased a new stake in shares of Natera in the fourth quarter valued at $32,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the third quarter valued at $44,000. Oliver Lagore Vanvalin Investment Group raised its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 389 shares during the period. Finally, CWM LLC raised its stake in shares of Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 911 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.